What question did this study set out to answer?

To assess the 1-year effects of the angiotensin II receptor antagonist olmesartan on blood pressure and renin-angiotensin-aldosterone system parameters in hypertensive outpatients.

January 1, 2001Hypertension ResearchOpen Access

Long-Term Effects of Olmesartan, an Ang II Receptor Antagonist, on Blood Pressure and the Renin-Angiotensin-Aldosterone System in Hypertensive Patients.

View Full Paper

Ask AI

Bookmark

Why the study?

Does olmesartan reduce blood pressure and alter renin-angiotensin-aldosterone parameters in hypertensive patients?

Population

n=26 hypertensive male and female outpatients, 38-69 years of age, with a systolic blood pressure ≥ 160 mmHg…

Design

Cohort

Follow-up

1 year

Authors

SIShûichi IchikawaToyohashi University of Technology YTYoshiaki TakayamaGunma University

Discussion

Member takes

Implication

Olmesartan-associated blood pressure reductions may inform hypertension care; leaves open causal RAAS effects pending randomized confirmation.

Key Points

To assess the 1-year effects of the angiotensin II receptor antagonist olmesartan on blood pressure and renin-angiotensin-aldosterone system parameters in hypertensive outpatients.
Conducted a prospective study evaluating 26 hypertensive outpatients (aged 38–69 years; baseline systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥95 mmHg).
Administered oral olmesartan at doses of 5 to 40 mg once daily.
Measured blood pressure, pulse rate, and hormonal parameters (plasma renin activity, angiotensin I, angiotensin II, and aldosterone) at baseline, 12–16 weeks, 6 months, and 1 year.
Systolic and diastolic blood pressure decreased significantly by 28.8 ± 2.1 mmHg and 15.8 ± 1.3 mmHg, respectively, after 1 year of treatment, with no change in pulse rate.
Plasma renin activity increased from a baseline mean of 1.26 ± 0.31 ng/ml/h to 2.58 ± 0.74 ng/ml/h at 6 months and 2.87 ± 0.72 ng/ml/h at 1 year.
Angiotensin II concentrations decreased significantly from 20.4 ± 3.2 pg/ml to 8.6 ± 2.1 pg/ml at 6 months and 6.8 ± 1.8 pg/ml at 1 year, alongside significant plasma aldosterone reductions at 6 months.

Structured PICO

Does olmesartan reduce blood pressure and alter renin-angiotensin-aldosterone parameters in hypertensive patients?

Population

n=26 hypertensive male and female outpatients, 38-69 years of age, with a systolic blood pressure ≥ 160 mmHg and/or a diastolic blood pressure ≥ 95 mmHg

Intervention

Olmesartan 5 to 40 mg oral once daily for 1 year

Outcome

Blood pressure and renin-angiotensin-aldosterone parameters (plasma renin activity and plasma angiotensin I, II, and aldosterone concentrations) evaluated at 12-16 weeks, 6 months, and 1 yearsurrogate

Long-term administration of olmesartan effectively lowers blood pressure and plasma angiotensin II levels in hypertensive patients.

Cite This Study

Ichikawa et al. (2001) studied this question.

synapsesocial.com/papers/6a7cecc0a0d4e77c65aeb517 https://doi.org/10.1291/hypres.24.641

Topics

Hypertension management

View Full Paper

Ask AI

Bookmark

Implication

Olmesartan-associated blood pressure reductions may inform hypertension care; leaves open causal RAAS effects pending randomized confirmation.

Long-Term Effects of Olmesartan, an Ang II Receptor Antagonist, on Blood Pressure and the Renin-Angiotensin-Aldosterone System in Hypertensive Patients.

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Topics

Long-Term Effects of Olmesartan, an Ang II Receptor Antagonist, on Blood Pressure and the Renin-Angiotensin-Aldosterone System in Hypertensive Patients.

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider